Reemployment premium effect of furlough programs: evaluating Spain's scheme during the COVID-19 crisis.

This paper presents an average treatment effect analysis of Spain's furlough program during the onset of the COVID-19 pandemic. Using 2020 labour force quarterly microdata, we construct a counterfactual made of comparable nonfurloughed individuals who lost their jobs and apply propensity score matching based on their pretreatment characteristics. Our findings show that the probability of being re-employed in the next quarter significantly increased for the treated (furlough granted group). These results appear robust across models, after testing a wide range of matching specifications that reveal a reemployment probability premium of near 30 percentage points in the group of workers who had been furloughed for a single quarter. Nevertheless, a different time arrangement affected the magnitude of the effect, suggesting that it may decrease with the furlough duration. Thus, an analogous analysis for a longer (two quarter) scheme estimated a still positive but smaller effect, approximately 12 percentage points. Although this finding might alert against long lasting schemes under persistent recessions, this policy still stands as a useful strategy to face essentially transitory adverse shocks.

Describing the immune response kinetics to mRNA COVID-19 vaccines among previously SARS-CoV-2-infected and -uninfected nursing home residents, a prospective longitudinal observational cohort evaluation-Georgia, October 2020 - September 2021

Background. To describe post-COVID-19 vaccination [fully vaccinated (FV) and first booster] immune response and occurrence of reinfection ( >90 days from prior infection) in nursing home residents (NHr) with/without evidence of prior SARS-CoV-2 infection. Methods. In a longitudinal prospective cohort of 36 NHr from 3 NHs, interviews, chart ions, and specimens [blood and anterior nasal swabs (ANs)] were collected at baseline and monthly visits. ANs underwent molecular and BinaxNOWTM antigen testing. Quantitative Meso Scale Discovery platform tested blood specimens for anti-spike (S) protein and anti-nucleocapsid (N) antibodies. In addition, in a subset (n=13), S-specific memory B cells (MBCs) were tested with ELISpot assays. Results. The cohort's median age was 72 years;46% male, 64% White Non-Hispanic, 80% had >=3 comorbidities, and 29 (81%) had prior SARS-CoV-2 infection. Of 36, 76% received Pfizer-BioNTech and 24% Moderna homologous vaccine. The median distribution of anti-S IgG concentrations among those with prior infection increased 15-30 days post-FV, remained stable for 90 days, and declined by 120 days. The anti-S IgG remained above the estimated vaccine effectiveness (VE) thresholds published [Pfizer-BioNTech (95% VE: 530 BAU/ml), Moderna (90% VE: 298 BAU/ml)]. Among those without previous infection, anti-S IgG declined after 60 days and stayed near the VE thresholds until a recent infection/booster. Age, sex, and comorbidities had no appreciable impact on anti-S IgG. From enrollment to November 2021, 1of 29 had reinfection. From December 2021 to January 2022, 2 of 7 had a new infection, and 4 of 29 had reinfection, as shown by anti-N IgG rise. Persistently low numbers of total and anti-S MBC were seen across the evaluation, even with post-booster anti-S MBC rise. There was an immediate rise in anti-S IgG concentrations in all participants post-booster, irrespective of recent infection. Conclusion. These findings from a NH convenience cohort suggest that prior SARS-CoV-2 infection has a pronounced immunomodulatory enhancing effect on the magnitude and duration of FV immune response. The decline of anti-S antibodies post-FV and rise after booster supported the booster recommendation in this cohort. The low MBC counts indicate immunosenescence in this high-risk population.

Evaluation of the airway viral load in acute sars-cov2 infection as a predictor of clinical outcome

Rationale: Throughout recent studies, data suggests high viral load in the plasma and nasopharynx of patients with severe SARS-CoV2 infection is associated with disease severity (mortality, length of hospitalization, and risk of intubation). Here, we evaluated whether viral load in the airway is associated with poor clinical outcomes in patients with SARS-CoV2. Methods: Lower airway samples in 148 patients from an academic center that were admitted to the ICU (dates: March 10th to May 10th, 2020) with severe respiratory failure requiring mechanical ventilation and underwent bronchoscopy for airway clearance and/or tracheostomy. Clinical outcome was defined as ≤ 28 Day mechanical ventilation vs. > 28 Day mechanical ventilation vs. death. Post-admission followup time was 232 [IQR 226-237] days. RNA was isolated in parallel using zymoBIOMICS™ DNA/RNA Miniprep Kit (Cat: R2002) as per manufacturer's instructions. Viral load was measured by quantitative real-time reverse transcription polymerase chain reaction (rRT -PCR) targeting the virus nucleocapsid (N) gene and an additional primer/probe set to detect the human RNase P gene (RP). Results: Among this bronchoscopy cohort, n=58 39% of the subjects were successfully extubated within 28 days of initiation of mechanical ventilation, n=56 38% required prolonged mechanical ventilation and n=34 23% died. We evaluated the viral load by rRT-PCR for SARSCoV2 N gene adjusted by human RP gene throughout the respiratory tract using supraglottic samples and bronchoalveolar lavage (BAL) samples obtained during bronchoscopy. Paired analysis of upper and lower airway samples shows that there is a subset of subjects (n=31, 21%) where there is greater viral load in the BAL than in the supraglottic area supporting topographical differences in viral replication (Fig 1A). BAL samples from subjects that died had higher viral load in their lower airways than patients that survived, even after adjusting for confounders such as age, gender, BMI and timing of sample collection (Fig 1B magenta dots (deceased) vs. yellow/green dots (alive)). Conclusions: Using samples obtained via bronchoscopy we identified that in a subset of subjects with acute SARS-CoV2 infection, the lower airways are the predominant site for viral replication. From our study, it is unclear if the higher viral load reflects host co-morbidies (e.g., diabetes or immunosuppression) or viral factors favoring higher replication. High viral load can be used as a predictor for disease severity upon hospital admission as viral load in the lower airways correlated with poor outcomes.

Evaluation of the lower airway microbiota in patients with severe sars-cov2

RATIONALE:Secondary infections with bacterial pathogens are thought to be responsible for poor outcomes in the 1918 Spanish and H1N1 pandemics. We postulate that poor prognosis in patients with SARS-CoV2 may be associated with uncontrollable viral replication, co-infection with a secondary pathogen, and over exuberant host immune response. We seek to evaluate whether there is an association between distinct features of the lower airway microbiota and poor clinical outcome in patients with SARS-CoV2. METHODS:We collected lower airway samples in 148 patients from NYU admitted between 3/10/2020 and 5/10/2020 with severe respiratory failure requiring mechanical ventilation and that underwent bronchoscopy for airway clearance and/or tracheostomy. Clinical outcome was defined as dead vs alive. DNA was isolated in parallel using zymoBIOMICS™ DNA/RNA Miniprep Kit (Cat: R2002) as per manufacturer's instructions. The V4 region of the 16S rRNA gene marker was sequenced using Illumina MiSeq. Sequences were analyzed using the Quantitative Insights into Microbial Ecology (QIIME version 1.9.1) pipeline. Total bacterial load was evaluated in lower airway samples using digital droplet PCR targeting the 16S rRNA gene. RESULTS:Of the 148 patients included, 114 survived (77%) and 34 (23%) died. Among those with poor clinical outcome, there was a non-statistically significant trend towards higher age and BMI. Patients who died more commonly had chronic kidney disease and prior cerebrovascular accidents, and more often required dialysis. There was no statistically significant difference in the rate of positive bacterial respiratory or blood cultures among those that survived vs. those that died (75 vs. 73% and 43 vs 38%, respectively). Topographical analysis of the 16S RNA microbiome shows compositional differences between the upper and lower airways based on β diversity comparisons. When comparing across clinical outcomes, the α diversity was lower in the dead group but there was no statistically significant difference in overall community composition (β diversity). Taxonomic differential enrichment analysis using DESeq analysis showed that oral commensals were enriched in the group that survived. Patients that died had a higher bacterial load in their lower airways than those who survived. CONCLUSION:Using samples obtained via bronchoscopy we identified lower airway microbiota signatures associated with mortality among critical patients infected with SARS-CoV2. Taxonomic signals identified as associated with poor prognosis did not reveal bacterial taxa commonly classified as respiratory pathogens. This data is not supportive of the hypothesis that secondary untreated bacterial co-infections are responsible for increased mortality in patients with severe SARS-CoV-2.

Home-Advantage during COVID-19: An Analysis in Portuguese Football League

Covid-19 pandemic forced, at the final rounds of 2019-2020 season, in many different sport leagues worldwide, teams to play without an audience. Therefore, the present paper aims to compare the home advantage score in the last ten rounds in 2019-2020 season with the first 24 rounds in same season using Pollard's (1986) and Matos et al.'s (2020) methods. In addition, comparisons across different seasons (2016-2017;2017-2018;2018-2019 and 2019-2020) using the same methods were also analyzed. Results showed no differences (p > 0.05) between first 24 rounds and the last 10 in 2019-2020 season as well as in the 3 previous seasons. With Pollard's method, no differences (p > 0.05) were also found among those four seasons on global (all 34 rounds) home advantage. However, a significance difference between 2017-2018 and 2019-2020 (p < 0.05) was founded using Matos et al.'s (2020) method, which is an indicator of the importance of using complementary methods when analyzing the same realities. Overall, despite what might be expectable from recent findings, the lack of an audience in the last 10 rounds of Portuguese Football League 2019-2020 season, due to COVID-19 pandemic, did not affect home advantage. Therefore, future studies could try to analyze other different variables in Portuguese Football League, such as referees' behaviors, rules changing (e.g., the possibility of making five substitutions, instead of three), crowd dimension and density as well as include variables about odds as forecasts in football being played without crowds.

Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.

BACKGROUND: Tocilizumab, an IL-6 receptor antagonist, can be used to treat cytokine release syndrome (CRS), with observed improvements in a coronavirus disease 2019 (COVID-19) case series. RESEARCH QUESTION: The goal of this study was to determine if tocilizumab benefits patients hospitalized with COVID-19. STUDY DESIGN AND METHODS: This observational study of consecutive COVID-19 patients hospitalized between March 10, 2020, and March 31, 2020, and followed up through April 21, 2020, was conducted by chart review. Patients were treated with tocilizumab using an algorithm that targeted CRS. Survival and mechanical ventilation (MV) outcomes were reported for 14 days and stratified according to disease severity designated at admission (severe, ≥ 3 L supplemental oxygen to maintain oxygen saturation > 93%). For tocilizumab-treated patients, pre/post analyses of clinical response, biomarkers, and safety outcomes were assessed. Post hoc survival analyses were conducted for race/ethnicity. RESULTS: Among the 239 patients, median age was 64 years; 36% and 19% were black and Hispanic, respectively. Hospital census increased exponentially, yet MV census did not. Severe disease was associated with lower survival (78% vs 93%; P < .001), greater proportion requiring MV (44% vs 5%; P < .001), and longer median MV days (5.5 vs 1.0; P = .003). Tocilizumab-treated patients (n = 153 [64%]) comprised 90% of those with severe disease; 44% of patients with nonsevere disease received tocilizumab for evolving CRS. Tocilizumab-treated patients with severe disease had higher admission levels of high-sensitivity C-reactive protein (120 vs 71 mg/L; P < .001) and received tocilizumab sooner (2 vs 3 days; P < .001), but their survival was similar to that of patients with nonsevere disease (83% vs 91%; P = .11). For tocilizumab-treated patients requiring MV, survival was 75% (95% CI, 64-89). Following tocilizumab treatment, few adverse events occurred, and oxygenation and inflammatory biomarkers (eg, high-sensitivity C-reactive protein, IL-6) improved; however, D-dimer and soluble IL-2 receptor (also termed CD25) levels increased significantly. Survival in black and Hispanic patients, after controlling for age, was significantly higher than in white patients (log-rank test, P = .002). INTERPRETATION: A treatment algorithm that included tocilizumab to target CRS may influence MV and survival outcomes. In tocilizumab-treated patients, oxygenation and inflammatory biomarkers improved, with higher than expected survival. Randomized trials must confirm these findings.

Repurposing antimicrobial stewardship tools in the electronic medical record for the management of COVID-19 patients.

During the COVID-19 pandemic, the antimicrobial stewardship module in our electronic medical record was reconfigured for the management of COVID-19 patients. This change allowed our subspecialist providers to review charts quickly to optimize potential therapy and management during the patient surge.